Barclays Maintains Overweight on Fate Therapeutics, Raises Price Target to $10
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Peter Lawson maintains an Overweight rating on Fate Therapeutics (NASDAQ:FATE) and raises the price target from $6 to $10.

February 27, 2024 | 2:37 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Barclays analyst Peter Lawson maintains an Overweight rating on Fate Therapeutics and raises the price target from $6 to $10.
The increase in price target by a reputable analyst suggests a positive outlook on the company's future performance, likely leading to increased investor confidence and a potential short-term rise in the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100